Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA SG&A

SG&A at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$163.9M+54.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$150.36M+97.2%
LQD
Liquidia CorporationLQDA
$46.94M+56.1%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$49.32M+5.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$96.33M+66.9%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$63.59M+62.7%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's SG&A?
Kiniksa Pharmaceuticals International, plc (KNSA) reported SG&A of $61.15M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's SG&A changed year-over-year?
Kiniksa Pharmaceuticals International, plc's SG&A increased by 40.5% year-over-year, from $43.53M to $61.15M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's SG&A?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's SG&A has grown at a 22.9% compound annual growth rate (CAGR), from $85.95M to $196.27M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.